Tesamorelin

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It acts at the pituitary gland to stimulate the body’s own pulsatile growth-hormone release, which in turn increases IGF-1 and can influence fat metabolism and body composition. The strongest controlled human data come from adults with excess abdominal fat in the setting of HIV-associated lipodystrophy. In that population, randomized studies demonstrated meaningful reductions in visceral adipose tissue and changes in liver fat and metabolic markers randomized clinical trial. Tesamorelin may support clinician-guided body-composition goals, with results depending on baseline health, nutrition, training, and the treatment plan.

Tesamorelin increases endogenous growth-hormone signaling, which can increase lipolysis and affect where fat is stored. The most distinctive part of the research is its effect on visceral adipose tissue rather than simply scale weight. In a 26-week randomized trial, visceral adipose tissue decreased by about 15% on average in the Tesamorelin group while increasing in the placebo group, with improvements in triglycerides and some other metabolic measures clinical research. That makes Tesamorelin especially relevant to body-composition conversations in a medspa setting.

Tesamorelin has been studied in randomized human trials, but it still requires clinician screening because it raises growth hormone and IGF-1 and can affect glucose metabolism. Your clinician will review your cancer history, pituitary function, glucose or diabetes risk, pregnancy status, medications, and other growth-hormone-axis therapies before prescribing it. Potential side effects can include injection-site reactions, fluid retention, joint or muscle discomfort, tingling, and changes in glucose regulation. In clinical research, glucose rose modestly early in treatment in some participants, which is one reason metabolic history matters trial.

Tesamorelin begins affecting GH/IGF-1 signaling early, but body-composition changes should be measured over months. Early waist or visual changes may begin to emerge around 8–12 weeks, while the strongest clinical data on visceral-fat reduction are measured at about 26 weeks, or 6 months. Progress is best tracked with waist measurements, photos, and body-composition testing rather than scale weight alone.

Bowery Clinic peptides are higher-strength and clinically dosed compared to most research facilities that use much lower concentrations. They are compounded by licensed 503A pharmacies with physician oversight and sterile quality standards, prioritizing real therapeutic outcomes over cheaper, unregulated research-grade products, and come fully prepared and ready for use — no mixing or reconstitution needed.

Yes. All pharmacies in our network are fully licensed in the states where they operate and comply with all state board of pharmacy regulations. Unlike many peptide clinics, we partner exclusively with FDA-registered U.S. pharmacies that undergo rigorous evaluation and compliance checks.

Every patient receives treatment plans developed and monitored by licensed providers. This includes safe titration of dosages and ongoing medical oversight tailored to individual needs.

Injections deliver the medication directly into your system. This makes the absorption more consistent and effective. Troches are small dissolvable lozenges that sit in your mouth until they melt, slowly releasing medication through the lining of your cheek or under your tongue.